Subhash Kukreja

Dr. Subhash Kukreja


Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2015 in Endocrine Practice
Verified
Journal Article
Closed access
EBElena Barengolts
Elena Barengolts
BMBuvana Manickam
Buvana Manickam
YEYuval Eisenberg
Yuval Eisenberg
AAArfana Akbar
Arfana Akbar
SKSubhash Kukreja
Subhash Kukreja
ICIrina Ciubotaru
Irina Ciubotaru

18 September 2012 in Archives of Osteoporosis
Verified
Journal Article
Closed access
PDF file
RMRaman K. Marwaha
Raman K. Marwaha
NTNikhil Tandon
Nikhil Tandon
YGYashdeep Gupta
Yashdeep Gupta
KBKuntal Bhadra
Kuntal Bhadra
ANArchana Narang
Archana Narang
SKSubhash Kukreja
Subhash Kukreja

15 July 2015 in Trials
Verified
Journal Article
Open access
PDF file
YEYuval Eisenberg
Yuval Eisenberg
HMHiba Mohiuddin
Hiba Mohiuddin
KCKarthik Cherukupally
Karthik Cherukupally
HZHassan Zaidi
Hassan Zaidi
SKSubhash Kukreja
Subhash Kukreja
EBElena Barengolts
Elena Barengolts
Randomized Clinical Trial (RCT) designs range from highly selective resulting in lack of external validity to more inclusive, requiring large sample sizes to observe significant results. Few publications, however, have compared excluded to enrolled participants. We aimed to assess our trial’s design based on the effectiveness versus efficacy continuum using the Pragmatic-Explanatory Continuum Indicator Summary (PRECIS) tool and to compare included and excluded patients. Fifteen members of endocrinology section completed PRECIS for DIVA (D-Vitamin Intervention in VA) trial; an RCT evaluating vitamin D supplementation in improving dysglycemia in patients with prediabetes. Retrospective chart review compared subjects excluded (OUT) to those included (IN) in RCT. Student’s t and Chi-square tests were used to compare continuous and categorical variables. Additionally, multiple logistic regression was completed. PRECIS scores were nearly universally pragmatic. 178 patients enrolled in DIVA trial were compared with 178 randomly selected patients excluded from study involvement. There was no significant difference between IN and OUT for the majority of the continuous and all of the categorical variables. Multivariate logistic regression identified only the A1c, HDL and Charlson Index as significant predictors of a participant’s inclusion or exclusion. There was higher HDL (51.3(13.9) versus 44.6(10.1), P = 0.001) and Charlson Index (2.85(1.6) versus 2.2(1.17), P = 0.001) for OUT versus IN groups. Subanalysis of excluded patients in A1c range 5.7 to 6.9, had lower BMI (30.7(3.4) versus 32(2.7), P = 0.002) but higher HDL (mg/l: 49.7(11.8) versus 44.6(10.1), P = 0.001) and Charlson index (2.85(1.6) versus 2.2(1.17), P = 0.001) than included participants. Additionally, there was a trend towards higher rates of cancer (22.9 % versus 12.9 %, P = 0.033) but less psychiatric problems (56.2 % versus 72.5 %, P = 0.026) and thiazide diuretic use (18.1 % versus 29.8 %, P = 0.034). DIVA trial design appears to favor broad clinical applicability. The majority of objectively compared variables did not different between patients included and excluded from this RCT. Advice based on the evidence from this RCT may be applicable to a larger group of patients than those fitting inclusion/exclusion criteria alone. ClinicalTrials.gov NCT01375660 (registered 15 June 2011).

1 June 2011
Verified
Book Chapter
Closed access
BMBuvana Manickam
Buvana Manickam
NVNancy Elizabeth Villagranan
Nancy Elizabeth Villagranan
ABAaron Benjamin
Aaron Benjamin
TWTerri Washington
Terri Washington
SKSubhash Kukreja
Subhash Kukreja
EBElena Barengolts
Elena Barengolts